Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
for Non-small Cell Lung Cancer (NSCLC)
15 locations incl. Phoenix
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06170788·Phase 3·Recruiting